In the phase II KEYNOTE-100 study of 376 patients with advanced recurring ovarian cancer, it was found that pembrolizumab monotherapy was linked to an ORR of 8.0% (95% CI [5.4–11.2]), and a higher PD-L1 expression level was also linked to a better response (Matulonis et al., 2019). Here, CD274 is linked to ovarian cancer.